You can take your $4 million and keep it. David Stout (photo [1]), GlaxoSmithKline's president of pharmaceutical operations, evidently wants no part of the reported $4 million incentive package [2] he was offered after being passed up [3]Â for the top job. The company reported this morning that he's on the way out, while another frustrated candidate, Chris Viehbacher (photo [4]), president of U.S. pharmaceuticals, joins the board. No word yet on where Stout may land. Andrew Witty (photo [5]), new chief, also took his place on the board. And Eddie Gray, currently senior vice president and general manager pharmaceuticals UK, will succeed Witty as president, pharmaceuticals Europe.
- check out the release [6] on the executive moves
Related Articles:
GSK runners-up get $4M, board seat. Report [2]
GSK CEO also-rans may get on board. Report [7]
At GSK, a public race for the top spot. Report [8]
Just who is Glaxo's Andrew Witty? Report [9]
GSK taps Witty as next CEO. Report [3]
Links:
[1] http://www.fiercebiotech.com/pages/gsks-david-stout
[2] http://www.fiercepharma.com/story/gsk-runners-up-get-4m-board-seat/2007-12-03?utm_medium=nl&utm_source=link
[3] http://www.fiercepharma.com/story/gsk-taps-witty-next-ceo/2007-10-08
[4] http://www.fiercebiotech.com/pages/gsks-chris-viehbacher
[5] http://www.fiercebiotech.com/story/glaxosmithkline-ceo-andrew-witty/2007-10-08
[6] http://www.fiercebiotech.com/press-releases/press-release-glaxosmithkline-announces-appointments-board-directors
[7] http://www.fiercepharma.com/story/gsk-ceo-also-rans-may-get-board/2007-10-16?utm_medium=rss&utm_source=pharma_David%20Stout
[8] http://www.fiercebiotech.com/story/gsk-public-race-top-spot/2007-09-24
[9] http://www.fiercepharma.com/story/just-who-glaxos-andrew-witty/2007-10-09